



☐☐☐

تم رفع هذه الرسالة بواسطة / حسام الدين محمد مغربي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

### ملاحظات:

ملاحظات:



# **Role of dynamic contrast enhanced MRI and Diffusion Weighted Imaging in Prediction of Tumor Response to TACE in Unresectable H.C.C Patients**

*Thesis*

*Submitted for Partial fulfillment of Doctorate  
Degree in Radio-diagnosis*

*Presented by*

**Ahmed Ibrahim Ibrahim Nassar**

*M.B. B. Ch., M.Sc.*

*Faculty of Medicine – Ain Shams University*

*Supervised by*

**Prof.Dr. Ahmed Mohamed Monib**

*Professor of Radio-diagnosis*

*Faculty of Medicine*

*Ain Shams University*

**Dr. Mohammed Sobhy Hassan**

*Assistant Professor of Radio-diagnosis*

*Faculty of Medicine*

*Ain Shams University*

**Dr. Ahmed Hassan Soliman**

*Assistant Professor of Radio-diagnosis*

*Faculty of Medicine*

*Ain Shams University*

*Faculty of Medicine*

*Ain Shams University*

*2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَقَ أَنْتَ لَا أَعْلَمُ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



*First and foremost, thanks to **Allah**, the most beneficial and most merciful. It is but for His mercy that we can put through in life.*

*I am greatly indebted to **Prof. Dr. Ahmed Mohamed Monib**, Professor of Radiology, ain shams University; for her great help, outstanding support and overwhelming kindness, and for her extreme patience, persistent guidance and understanding. She enlightened my path and guided my footsteps through many obstacles. I really owe her much.*

*I am also very grateful to **Prof. Dr. Mohammed Sobhy Hassan** Professor of Radiology, Ain Shams University and **Dr. Ahmed Hassan Soliman** Assistant Professor of Radiology, Ain Shams University for their support, simplicity in handling matters, stimulating suggestions, and encouragement.*

*And last but certainly not least, My heartfelt thanks to my dear wife, my sweaty daughter and my family members, for their assistance, encouragement, patience and support throughout my work,*

*Finally, many thanks are due to my friends and fellow colleagues in the Radiology Department. Their support and encouragement had certainly been overwhelming.*

# List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables.....	iv
List of Figures .....	v
Introduction .....	1
Aim of the Work .....	4
Review of Literature	
▪ Chapter 1: MRI Anatomy of the Liver .....	5
▪ Chapter 2: Pathological Aspects of HCC .....	13
▪ Chapter 3: Principles of Diffusion-Weighted MR Imaging .....	25
▪ Chapter 4: MR Imaging Techniques and Concepts of The Liver.....	39
▪ Chapter 5: MRI Appearance of HCC .....	56
▪ Chapter 6: The Role of Transcatheter Arterial Chemoembolization (TACE) in Treatment of HCC .....	85
▪ Chapter 7: Role of Diffusion and Dynamic MRI in Assessment of Post TACE Necrosis of HCC .....	103
Subjects and Methods .....	131
Results.....	139
Illustrated Cases .....	151
Discussion .....	224
Summary and Conclusion.....	231
References .....	235
Arabic Summary .....	—

## *List of Abbreviations*

Abb.	Full term
3D.....	Three-dimensional
AASLD.....	Association for the study of liver diseases
ADC .....	Apparent diffusion coefficient
AFP .....	Alpha fetoprotein
APF .....	Arterioportal fistula
APHE.....	Arterial phase hyper-enhancement
BBEPI .....	Black-blood echo-planar imaging
BCLC .....	Barcelona clinic liver cancer
CNR .....	Contrast-to-noise ratio.
DCE MRI .....	Dynamic contrast-enhanced MRI
DEB-TACE .....	Drug-eluting beads transarterial chemoembolization
DM .....	Diabetes mellitus
DWI.....	Diffusion-weighted magnetic resonance imaging
ETL .....	Echo train length
FL.....	Falciform ligament
FSE/TSE .....	Fast/turbo spin echo
GRAPPA .....	Generalized auto- calibrating partially parallel acquisition
GRE .....	Gradient echo
H.C.C .....	Hepatocellular carcinoma
HASTE.....	Half acquisition single shot turbo echo
HIV .....	Human immunodeficiency virus
IBR.....	Institutional board review
ICC.....	Intrahepatic cholangiocarcinoma
IP.....	In-phase
IVC.....	Inferior vena cava

## *List of Abbreviations Cont...*

<b>Abb.</b>	<b>Full term</b>
<b>IVIM</b> .....	Intravoxel incoherent motion
<b>LAVA</b> .....	Liver acquisition with volume acceleration
<b>Lga</b> .....	Left gastric artery
<b>Lha</b> .....	Left hepatic artery
<b>LHV</b> .....	Left hepatic vein
<b>LI-RADS</b> .....	Liver imaging-reporting and data system
<b>LR-TIV</b> .....	LR-tumor in vein
<b>LR-TR</b> .....	Liver imaging reporting and data system treatment response
<b>LV</b> .....	Ligamentum venosum
<b>MDCT</b> .....	Multi-detector computed tomography
<b>Mha</b> .....	Middle hepatic artery
<b>MHV</b> .....	Middle hepatic vein
<b>MIP</b> .....	Maximum intensity projection
<b>MRCP</b> .....	Magnetic resonance cholangiopancreatography
<b>MRI</b> .....	Magnetic resonance imaging
<b>NEX</b> .....	Number of excitations
<b>NPV</b> .....	Negative predictive value
<b>NSF</b> .....	Nephrogenic systemic fibrosis
<b>OLT</b> .....	Orthotropic liver transplantation
<b>OP</b> .....	Out-of-phase
<b>PEI</b> .....	Percutaneous ethanol injection
<b>PI</b> .....	Parallel imaging
<b>PPV</b> .....	Positive predictive value
<b>RF</b> .....	Radiofrequency.
<b>RFA</b> .....	Radiofrequency ablation
<b>Rha</b> .....	Right hepatic artery

## *List of Abbreviations Cont...*

Abb.	Full term
<b>RHV</b> .....	Right hepatic vein
<b>RT</b> .....	Radiation therapy
<b>R-T</b> .....	Respiratory-triggered
<b>SE</b> .....	Single-shot spin-echo
<b>Sma</b> .....	Superior mesenteric artery
<b>SNR</b> .....	Signal to noise ratios.
<b>SPAIR</b> .....	Spectrally adiabatic inversion recovery
<b>SPIO</b> .....	Superparamagnetic iron oxide particle
<b>SPSS</b> .....	Statistical package for the social sciences
<b>SSFSE</b> .....	Single shot fast spin echo.
<b>STIR</b> .....	Short time inversion recovery sequences
<b>TACE</b> .....	Trans-arterial chemo-embolization
<b>TAE</b> .....	Trans-arterial embolization
<b>TARE</b> .....	Trans arterial radio-embolization
<b>TE</b> .....	Echo time
<b>TR</b> .....	Time of repetition
<b>TVDT</b> .....	Tumor volume doubling time
<b>WO</b> .....	Wash-out



## *List of Tables*

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Table (1):</b>	Visual liver lesion characterization with DW MR imaging. ....	32
<b>Table (2):</b>	LI-RADS diagnostic categories. LI-RADS diagnostic categories (on the left) and examples of LR-1 and LR-2 entities (on the right). ....	58
<b>Table (3):</b>	List of LI-RADS ancillary features. ....	69
<b>Table (4):</b>	MRI protocol for post-treatment response assessment. ....	103
<b>Table (5):</b>	Expected appearances after TACE therapy. ....	114
<b>Table (6):</b>	Overview of response criteria and categories. ....	119
<b>Table (7):</b>	LI-RADS treatment response categories. ....	124
<b>Table (8):</b>	The demographic data of 20 treated observations. ....	139
<b>Table (9):</b>	Minimum and maximum diameter of the lesions in mm. ....	142
<b>Table (10):</b>	Correlation between dynamic MRI results to the final diagnosis in the studied group. ....	146
<b>Table (11):</b>	Correlation between diffusion MRI results to the final diagnosis in the studied group. ....	148
<b>Table (12):</b>	Statistical analysis of ADC value results to the final diagnosis in the studied group. ....	150

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	T1 and T2 WIs appearance of the liver. ....	7
<b>Figure (2):</b>	(a–g): Segmental liver anatomy in MRI. ....	10
<b>Figure (2):</b>	(h and i): Hepatic veins and portal vein in MRI. ....	11
<b>Figure (2):</b>	(j, k and l): hepatic arteries ....	12
<b>Figure (3):</b>	Microscopic appearance of Growth patterns of H.C.C.....	18
<b>Figure (4):</b>	Microscopic appearance of hepatocellular carcinoma variants .....	21
<b>Figure (5):</b>	Schematic illustrates water molecule movement .....	26
<b>Figure (6):</b>	Schematic illustrates the effect of a DWI imaging on water molecules.....	29
<b>Figure (7):</b>	Signal intensity versus b values at diffusion-weighted imaging (DWI) and ADC in different tissues.....	33
<b>Figure (8):</b>	Example for T2 shine-through effect in a cyst .....	35
<b>Figure (9):</b>	Importance of a multichannel array receiver coil .....	42
<b>Figure (10):</b>	T1 FS (VIBE) sequences .....	51
<b>Figure (11):</b>	Typical liver MRI protocol .....	55
<b>Figure (12):</b>	Non-rim and rim APHE .....	60
<b>Figure (13):</b>	LI-RADS diagnostic algorithm .....	62
<b>Figure (14):</b>	Washout appearance.....	63
<b>Figure (15):</b>	Capsule appearance of H.C.C .....	67
<b>Figure (16):</b>	Restricted diffusion in HCC.....	71
<b>Figure (17):</b>	Corona enhancement of HCC .....	74

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (18):</b>	Difference of fat deposition in a mass more than the surrounding liver and fat sparing in a mass in a diffusely fatty liver.....	76
<b>Figure (19):</b>	Mosaic architecture and nodule in nodule appearance of HCC.....	78
<b>Figure (20):</b>	Step 1 of the LI-RADS v2018.....	82
<b>Figure (21):</b>	Step 2 of the LI-RADS v2018.....	83
<b>Figure (22):</b>	Step 3 of the LI-RADS v2018.....	84
<b>Figure (23):</b>	Principle of conventional trans-arterial chemoembolization .....	86
<b>Figure (24):</b>	Arterioportal fistula (APF) post TACE.....	94
<b>Figure (25):</b>	Bile duct injury post TACE .....	97
<b>Figure (26):</b>	Post-TACE acute parenchymal infarction .....	99
<b>Figure (27):</b>	Post-TACE tumor rupture.....	100
<b>Figure (28):</b>	CT scans of patterns of lipiodol accumulation after TACE .....	105
<b>Figure (29):</b>	MRI appearance of complete necrosis of HCC focal lesion after TACE in T1 and T2 WIs .....	108
<b>Figure (30):</b>	MRI appearance of residual HCC focal lesion. ....	109
<b>Figure (31):</b>	CT and MRI appearance of residual HCC focal lesion.....	110
<b>Figure (32):</b>	CT and MRI appearance of trans-catheter arterial chemo-embolization (TACE)-induced arterioportal shunt, portal vein obliteration and infarct. ....	112

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (33):</b>	CT appearance of Hepatocellular carcinoma (HCC) treated with DEB-TACE .....	115
<b>Figure (34):</b>	Pre and Post-TACE MRI appearance of HCC focal lesion showing post treatment viability. ....	116
<b>Figure (35):</b>	CT appearance of presence of gas as a findings specific to trans-catheter therapies. ....	117
<b>Figure (36):</b>	Pre and post-TACE CT appearance of treated HCC focal lesion. ....	118
<b>Figure (37):</b>	LI-RADS treatment response algorithm with tie-breaking rules .....	120
<b>Figure (38):</b>	Expected post-treatment thin enhancing rim.....	121
<b>Figure (39):</b>	Pre and post-treatment CT appearance of Hepatocellular carcinoma (HCC) with tumor in vein .....	122
<b>Figure (40):</b>	Measurements of viable tumor after treatment.....	123
<b>Figure (41):</b>	Pre and Post-TACE DWI with ADC histograms.....	127
<b>Figure (42):</b>	Perilesional recurrence of HCC after chemoembolization .....	128
<b>Figure (43):</b>	Distribution of patients according to AFP level .....	139
<b>Figure (44):</b>	Distribution of lesions into LR-TR viable, non-viable and non-evaluable groups.....	141

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (46):</b>	Distribution of signal intensity of LR-TR non-viable conditions on T1 WIs .....	143
<b>Figure (47):</b>	Distribution of signal intensity of LR-TR non-viable conditions on T2 WIs .....	143
<b>Figure (48):</b>	Distribution of signal intensity of LR-TR viable lesions on T1 WIs.....	144
<b>Figure (49):</b>	Distribution of signal intensity of LR-TR viable lesions on T2 WIs.....	144
<b>Figure (50):</b>	Distribution of lesion border in both benign and malignant conditions. ....	145
<b>Figure (51):</b>	Diagnostic indices (sensitivity, specificity, PPV, NPV and overall agreement) of dynamic and diffusion MRI in the studied group.....	149
<b>Figure (52):</b>	Results of receiver operating curves for ADC values in distinguishing LR-TR non-viable and LR-TR viable groups.....	150
<b>Figure (53-62):</b>	Case 1 .....	151
<b>Figure (63-68):</b>	Case 2 .....	161
<b>Figure (69-74):</b>	Case 3 .....	168
<b>Figure (75-85):</b>	Case 4 .....	175
<b>Figure (86-92):</b>	Case 5 .....	187
<b>Figure (93-97):</b>	Case 6 .....	194
<b>Figure (98-106):</b>	Case 7 .....	201
<b>Figure (107-111):</b>	Case 8 .....	212
<b>Figure (112-116):</b>	Case 9 .....	218
<b>Figure (117):</b>	Follow-up post treatment algorithm suggested by LIRADS 2018 version .....	230

# **Role of dynamic contrast enhanced MRI and Diffusion Weighted Imaging in Prediction of Tumor Response to TACE in Unresectable H.C.C Patients**

**Ahmed Ibrahim Nassar<sup>1</sup>, Ahmed Mohamed Monib<sup>2</sup>, Mohamed Sobhy Hassan<sup>3</sup>, Ahmed Hassan Soliman<sup>4</sup>**

<sup>1</sup>Radio-diagnosis specialist, El-Agouza police hospital, <sup>2</sup>Professor of Radio-diagnosis, Faculty of Medicine / Ain-shams University, <sup>3</sup> Professor of Radio-diagnosis, Faculty of Medicine / Ain-shams University, <sup>4</sup> Assistant Professor of Radio-diagnosis, Faculty of Medicine / Ain-shams University.

## **Abstract**

**Background:** To evaluate the role of MRI in the detection of recurrent or residual tumor viability in prediction of the response of the irresectable HCC patients who had locally treated with TACE by studying the enhancement (vascularity) pattern and the volume changes of the HCC after TACE. We were also aiming to improve the technique and to standardize MR protocol to be used after interventional therapy for malignant hepatic tumors.

**Results:** The study group consisted of 20 patients and the results were analyzed as 31 treated hepatic focal lesions. The patients underwent DCE MRI with DWI in one / three months duration following TACE procedure and were radiologically assessed to observe tumoral post treatment response for non-viable, viable post treatment response categories Statistical analysis showed that dynamic MRI had 100% level of sensitivity, specificity of 88.89 %, PPV of 91.67% and NPV of 100% with an overall agreement of 95%. While on the other hand, statistics showed that DWI has 81.82 % level of sensitivity, specificity of 88.9%, PPV of 90%, NPV of 80% with an overall agreement of 85%. The difference between non-viable and viable groups' ADC variables was found statistically significant at P value < 0.018 and best cut off value that augments sensitivity and specificity is 1.24. At this ADC value, showed 90.91% level of sensitivity, specificity of 87.5%, PPV of 90.9%, NPV of 87.50% with an overall agreement of 79.5%.

**Conclusion:** Dynamic contrast enhanced MRI is a powerful tool in detection of tumour viability and complications after TACE of hepatocellular carcinoma. Imaging protocol should include dynamic study combined with diffusion imaging with post processing of the images to obtain ADC measurements for better tissue characterization and should be performed at regular time intervals to enhance the diagnostic confidence of MRI for post treatment response viability detection.

**Keywords:** HCC–TACE– DCE MRI –DWI.

# INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary malignant disease of the liver and is the third leading cause of death from cancer worldwide (*Bonekamp et al., 2013*).

Only a minority of all patients with HCC are surgical candidates at the time of diagnosis (*Wang et al., 2014*).

Treatment options are divided into surgical therapies (i.e., resection, cryoablation and orthotopic liver transplantation (OLT), and nonsurgical therapies (i.e., percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), trans-arterial chemo-embolization (TACE), radiation therapy (RT) and systemic therapy) (*Curley et al., 2017*).

Transcatheter arterial chemoembolization (TACE) is one of the most commonly used intra-arterial therapies to treat unresectable HCC, and several clinical trials have demonstrated that TACE has the potential to show survival benefits in patients with HCC. TACE is a frequently used technique and usually includes intra-arterial delivery of emulsions mixed with chemotherapeutic agents and lipiodol, followed by the administration of the embolic agent (*Wang et al., 2014*).

Assessing early response to therapy using objective criteria is paramount for clinical care. Identifying early responders could help individualize therapy and tailor future treatment strategies (*Bonekamp et al., 2013*).